CGNX insider sale notice: 4,002 shares via Morgan Stanley

Rhea-AI Filing Summary

Form 144 notice for Cognex Corp (CGNX): This filing notifies the proposed sale of 4,002 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $177,168.54. The shares represent restricted stock units acquired from the issuer on 02/22/2023 and the filer lists the approximate date of sale as 09/05/2025 on the NASDAQ. The filing reports no securities sold in the past three months for the account and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR Routine insider-sale notice for a small position relative to outstanding shares, unlikely to move valuation.

The filing is a standard Form 144 notifying a brokered sale of 4,002 common shares executed via Morgan Stanley Smith Barney LLC. The shares came from restricted stock units granted and vested on 02/22/2023. With 167,899,010 shares outstanding, the proposed sale equals roughly 0.0024% of the share count, indicating immaterial supply pressure. The absence of sales in the prior three months and the inclusion of the Rule 10b5-1/representation language are consistent with compliance-focused dispositions rather than signaling company-wide news.

Corporate Governance Expert

TL;DR Compliance-focused disclosure; provides transparency on insider liquidity but no governance red flags.

The document discloses the origin of the shares as issuer-granted RSUs and names the executing broker, fulfilling Rule 144 disclosure requirements. There are no indications of accelerated or unusual sales activity and the filer affirms no undisclosed material adverse information. From a governance perspective, this is a routine compliance filing that documents an insider monetization event without presenting material governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4002	177168.54	167899010	09/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/22/2023	Restricted Stock Units	Issuer			4002	02/22/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the CGNX Form 144 report?

The filing notifies a proposed sale of 4,002 common shares of Cognex Corp through Morgan Stanley Smith Barney LLC with an aggregate market value of $177,168.54.

When were the shares acquired that are being sold under the Form 144?

The shares were acquired as restricted stock units from the issuer on 02/22/2023.

What is the approximate sale date listed in the CGNX Form 144?

The filing lists the approximate date of sale as 09/05/2025 and the intended exchange as NASDAQ.

Has the filer sold any Cognex (CGNX) securities in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

What type of representation does the filer make in the filing?

The filer represents by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed and references Rule 10b5-1 compliance language.